Clinical Trial Update: Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

This Clinical Trial Update reports completion of a Phase I/II study of MEDI522 in irinotecan-refractory advanced colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• MEDI522

Snippet

Sponsor: MedImmune LLC | Conditions: Cancer | Phase 1, Phase 2 | Status: COMPLETED